ReviewAllergo journal international2018
Novel vaccines targeting dendritic cells by coupling allergoids to mannan.
Review in Allergo journal international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05400811 (Prospective, Randomised, DBPC, Double-dummy, Multicenter CT of Efficacy and Safety With IT in Patients With Controlled Mild to Moderate Allergic Asthma and Rhinitis/Rhinoconjunctivitis, Allergic to D. Pteronyssinus and/or D. Farinae.), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Randomised, DBPC, Double-dummy, Multicenter CT of Efficacy and Safety With IT in Patients With Controlled Mild to Moderate Allergic Asthma and Rhinitis/Rhinoconjunctivitis, Allergic to D. Pteronyssinus and/or D. Farinae.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Trial
- Trial
- Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study.Frontiers in immunology · 2024Trial
- First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.Allergy · 2022Trial
- Short-Course Subcutaneous Immunotherapy With Mannan-Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements.Clinical and translational allergy · 2026Article
- Subcutaneous Immunotherapy with Mannan-Conjugated Birch Pollen Allergoids in a Pre- and Co-Seasonal Treatment Regimen: An Exploratory Post Hoc Subgroup Analysis of Safety and Tolerability.Journal of clinical medicine · 2026Article
- Clinical Efficacy of One Short Course of Mannan-Conjugated Birch Pollen Allergoid Immunotherapy: A Comparative Evaluation After Prior Placebo Treatment.Journal of clinical medicine · 2025Article
- Immunogenicity of mannan derived fromIranian journal of microbiology · 2024Article
- A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action.Frontiers in immunology · 2024Review
- C-Type Lectin Receptor Mediated Modulation of T2 Immune Responses to Allergens.Current allergy and asthma reports · 2023Review
- Dynamic Imine Bonding Facilitates Mannan Release from a Nanofibrous Peptide Hydrogel.Bioconjugate chemistry · 2023Article
- Mechanisms in AIT: Insights 2021.Allergologie select · 2022Review
- Review
- Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance.Frontiers in immunology · 2021Review
- Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy.Pharmaceutics · 2020Review
- Article
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
- Der p 2.1 Peptide Abrogates House Dust Mites-Induced Asthma Features in Mice and Humanized Mice by Inhibiting DC-Mediated T Cell Polarization.Frontiers in immunology · 2020Article
- Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors.Frontiers in immunology · 2020Review
- Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive research to develop alternative strategies, including novel administration routes, adjuvants or hypoallergenic molecules. Promising results are reported for some of them, but clinical progress is still moderate. Allergoids conjugated to nonoxidized mannan from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.